分子标志物在食管癌骨髓微转移中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2013.11.012

国际肿瘤学杂志 ›› 2013, Vol. 40 ›› Issue (11): 839-843.doi: 10.3760/cma.j.issn.1673-422X.2013.11.012

分子标志物在食管癌骨髓微转移中的研究进展

马兰, 刘连科

南京医科大学第一附属医院肿瘤科

出版日期:2013-11-08 发布日期:2013-10-15
通讯作者: 刘连科， E-mail:liulianke@medmail.com.cn E-mail:liulianke@medmail.com.cn
基金资助:
江苏省临床医学科技专项（BL2012008）

Molecular markers in the bone marrow micrometastasis of esophageal cancer

MA Lan, LIU Lian-Ke

Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

Online:2013-11-08 Published:2013-10-15
Contact: LIU Lian-Ke, E-mail:liulianke@medmail.com.cn E-mail:liulianke@medmail.com.cn

摘要/Abstract

摘要： 近年食管癌骨髓微转移逐渐成为研究热点。许多研究显示上皮细胞分子、血管形成相关标志物、趋化因子受体-4（CXCR-4）、HER2基因、活化白细胞黏附分子（ALCAM）及斯钙素-1（STC-1）等分子标志物与食管癌骨髓微转移密切相关，这些分子标志物对食管癌临床诊断、预后判断及指导治疗有重要作用。

关键词: 食管肿瘤, 肿瘤微转移, 肿瘤标记, 生物学

Abstract: In recent years, the bone marrow micrometastasis of esophageal cancer has become the research focus. Many studies show that epithelial cell molecules, angiogenesis markers, chemokine receptor-4 (CXCR-4), HER2, activated leukocyte cell adhesion molecule (ALCAM) and stanniocalcin-1 (STC-1) are closely related to the bone marrow micrometastasis of esophageal cancer. These molecular markers play important roles in esophageal cancer diagnosis, prognosis and treatment.

Key words: Esophageal neoplasms, Neoplasm micrometastasis, Tumor markers, biological

马兰, 刘连科. 分子标志物在食管癌骨髓微转移中的研究进展[J]. 国际肿瘤学杂志, 2013, 40(11): 839-843.

MA Lan, LIU Lian-Ke. Molecular markers in the bone marrow micrometastasis of esophageal cancer[J]. Journal of International Oncology, 2013, 40(11): 839-843.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2) :69-90. ［2］ Nieman DR, Peters JH. Treatment strategies for esophageal cancer. Gastroenterol Clin North Am, 2013,42(1):187-197. ［3］ Kutup A, Yekebas EF, Izbicki JR. Current diagnosis and future impact of micrometastases for therapeutic strategies in adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results Cancer Res, 2010,182:115-125. ［4］ Zhang X, Chen SB, Chen JX, et al. CK19 mRNA expression in the bone marrow of patients with esophageal squamous cell carcinoma and its clinical significance. Dis Esophagus, 2010,23(5):437-443. ［5］ Makino T, Yamasaki M, Takeno A, et al. Cytokeratins 18 and 8 are poor prognostic markers in patients with squamous cell carcinoma of the oesophagus. Br J Cancer, 2009, 101(8):1298-1306. ［6］ UsnarskaZubkiewicz L, StrutynskaKarpinska M, PodolakDawidziak M, et al. Epithelial bone marrow cells in patients with advanced esophageal squamous cell carcinoma. Neoplasma, 2009,56(3):245-251. ［7］ Zhang QB, Gao YP, He JT, et al. Establishment of a novel human esophageal squamous cell carcinoma cell line(ESC-410) and its partial biological characterization. Dis Esophagus, 2011, 24(2):120-126. ［8］ Bagheri R, Maddah G, Saedi HS, et al. Bone marrow involvement in esophageal cancer patients who underwent surgical resection. Eur J Cardiothorac Surg, 2011,40(2):343-346. ［9］ Vashist YK, Effenberger KE, Vettorazzi E, et al. Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer. Ann Surg, 2012,255(6):1105-1112. ［10］ Kaifi JT, Yekebas EF, Schurr P, et al. Tumorcell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst, 2005,97(24):1840-1847. ［11］ Schultze A, Ben Batalla I, Riethdorf S, et al. VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma. Clin Exp Metastasis, 2012,29(8):879-887. ［12］ Gray RT, O′Donnell ME, Verghis RM, et al. Bone marrow micrometastases in esophageal carcinoma: a 10-year follow-up study. Dis Esophagus, 2012,25(8):709-715. ［13］ Spence GM, Graham AN, Mulholland K, et al. Bone marrow micrometastases and markers of angiogenesis in esophageal cancer. Ann Thorac Surg, 2004,78(6):1944-1949. ［14］ Tachezy M, Effenberger K, Zander H, et al. ALCAM (CD166) expression and serum levels are markers for poor survival of esophageal cancer patients. Int J Cancer, 2012,131(2):396-405. ［15］ Van de Veire S, Stalmans I, Heindryckx F, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell, 2010,141(1):178-190. ［16］ Gros SJ, Graeff H, Drenckhan A, et al. CXCR4/SDF-1α-mediated chemotaxis in an in vivo model of metastatic esophagealcarcinoma. In Vivo, 2012,26(4):711-718. ［17］ Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell, 2008,13(5):441-453. ［18］ Hjortland GO, Meza-Zepeda LA, Beiske K, et al. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer, 2011,11:455. ［19］ Gros SJ, Kurschat N, Drenckhan A, et al. Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One, 2012,7(10):e47287. ［20］ Weidle UH, Eggle D, Klostermann S, et al. ALCAM/CD166: cancer-related issues. Cancer Genomics Proteomics, 2010,7(5):231-243. ［21］ Shirakawa M, Fujiwara Y, Sugita Y, et al. Assessment of stanniocalcin-1 as a prognostic marker in human esophageal squamous cell carcinoma. Oncol Rep, 2012,27(4):940-946. ［22］ Song H, Xu B, Yi J. Clinical significance of stanniocalcin-1 detected in peripheral blood and bone marrow of esophageal squamous cell carcinoma patients. J Exp Clin Cancer Res, 2012, 31:35.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[4]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[5]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟. 基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[6]	山东省医学会肺癌食管癌多学科联合委员会. 山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[7]	刘博翰, 黄俊星. 溶质载体SLC7A5及SLC7A11基因在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(5): 280-284.
[8]	冀世玉, 张明鑫, 谢华红, 白渊, 王彤. 不同支架治疗晚期食管癌患者的疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 76-81.
[9]	巩合义, 伊艳, 张健, 李宝生. 局部晚期可手术食管癌经新辅助放化疗达临床完全缓解后的处理策略[J]. 国际肿瘤学杂志, 2023, 50(12): 745-750.
[10]	金明, 甄书青, 王彦巧, 申红霞, 张爱民, 回丽妹. 丙泊酚对前列腺癌DU145细胞恶性生物学行为的影响及其机制[J]. 国际肿瘤学杂志, 2022, 49(8): 453-458.
[11]	吴浦嫄, 祁亮, 王涛, 史敏科, 孙雨薇, 王立峰, 刘宝瑞, 闫婧, 任伟. 基于高频复发区改良临床靶区的术后放疗在食管鳞状细胞癌中的疗效研究[J]. 国际肿瘤学杂志, 2022, 49(8): 464-472.
[12]	戴李宸, 胡莉钧, 于静萍. 尼妥珠单抗治疗食管鳞状细胞癌的应用进展[J]. 国际肿瘤学杂志, 2022, 49(8): 484-489.
[13]	夏玲玲, 陈永顺, 李彬, 宁婷婷, 张蔡羽天. pN₊食管鳞状细胞癌患者R0切除术后放化疗与化疗的安全性及有效性比较[J]. 国际肿瘤学杂志, 2022, 49(6): 334-339.
[14]	叶倩, 凌志, 刘申香, 路国涛, 殷旭东. 肌肉减少症对老年食管癌患者根治性放疗临床疗效及预后的影响[J]. 国际肿瘤学杂志, 2022, 49(4): 199-205.
[15]	周剑烽, 王铁君. 食管癌的靶向治疗及免疫治疗[J]. 国际肿瘤学杂志, 2022, 49(4): 237-242.

分子标志物在食管癌骨髓微转移中的研究进展

Molecular markers in the bone marrow micrometastasis of esophageal cancer

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价